LCM
ACRS icon

Landscape Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Landscape Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,469
Closed -$307K – 452
2017
Q4 		$307K Buy
+12,469
New +$304K 0.03% 481

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Landscape Capital Management's ACRS Position: Q1 2018 in Review

Landscape Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2018, closing a stake of 12,469 shares — an estimated $307K sold.

Landscape Capital Management first reported a position in ACRS in Q4 2017 and held it in 1 quarter. The position peaked at $307K in Q4 2017. 100 funds tracked by Wall St. Rank hold ACRS as of Q1 2018.

  • Landscape Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Landscape Capital Management sold 12,469 Aclaris Therapeutics shares in Q1 2018, an estimated $307K.
  • Landscape Capital Management first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 1 quarter.
  • Landscape Capital Management's Aclaris Therapeutics position peaked at $307K in Q4 2017.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2018.

Based on Landscape Capital Management's 13F filing for Q1 2018, filed 11 May 2018.